Global coalition for adaptive research, biohaven, and vigeo announce commencement of biohaven's troriluzole and vigeo's vt1021 in gbm agile trial

Larkspur, calif.--(business wire)-- #gbmagile--global coalition for adaptive research (larkspur, ca), biohaven pharmaceutical holding company ltd. (nyse: bhvn), and vigeo therapeutics -- the global coalition for adaptive research (gcar) in collaboration with biohaven and vigeo therapeutics, today announced the activation of biohaven's troriluzole and vigeo's vt1021 in gbm agile (glioblastoma adaptive global innovative learning environment). gbm agile is a revolutionary patient-centered, adaptive platform t
BHVN Ratings Summary
BHVN Quant Ranking